Skip to content
2000
Volume 25, Issue 13
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Objective

This study systematically evaluated the efficacy and safety of Ling Gui Zhu Gan Decoction for treating non-alcoholic fatty liver disease.

Methods

Registered under CRD42024501460 on the PROSPERO platform, we searched eight major databases, including Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang database, Chinese Scientific Journals Database, and Chinese Biomedicine Database, from inception to December 2023 for randomized controlled trials on Ling Gui Zhu Gan Decoction in non-alcoholic fatty liver disease treatment. We extracted data on total efficiency, TC, TG, ALT, AST, GGT, and HOMA-IR, analyzing results with RevMan 5.4 software.

Results

Twelve studies met the inclusion criteria, encompassing 970 cases. Ling Gui Zhu Gan Decoction, alone or combined with standard therapy, significantly improved non-alcoholic fatty liver disease outcomes, regardless of treatment duration. Only one study reported adverse events, including bloating, diarrhea, nausea, vomiting, and rash.

Conclusion

Ling Gui Zhu Gan Decoction appears to be an effective and safe option for non-alcoholic fatty liver disease treatment. However, due to limited studies and methodological weakness, further rigorous randomized controlled trials are necessary for conclusive results.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303323071241022053842
2025-01-09
2026-01-01

  • From This Site

    /content/journals/emiddt/10.2174/0118715303323071241022053842
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/13/EMIDDT-25-13-04.html?itemId=/content/journals/emiddt/10.2174/0118715303323071241022053842&mimeType=html&fmt=ahah

References

  1. MauriceJ. ManousouP. Non-alcoholic fatty liver disease.Clin. Med. (Lond.)201818324525010.7861/clinmedicine.18‑3‑24529858436
     [Google Scholar]
  2. YounossiZ.M. KoenigA.B. AbdelatifD. FazelY. HenryL. WymerM. Global epidemiology of nonalcoholic fatty liver disease — Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016641738410.1002/hep.2843126707365
     [Google Scholar]
  3. SinnD.H. KangD. ChangY. RyuS. GuS. KimH. SeongD. ChoS.J. YiB.K. ParkH.D. PaikS.W. SongY.B. LazoM. LimaJ.A.C. GuallarE. ChoJ. GwakG.Y. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: A retrospective cohort study.Gut201766232332910.1136/gutjnl‑2016‑31185427599521
     [Google Scholar]
  4. FriedmanS.L. Neuschwander-TetriB.A. RinellaM. SanyalA.J. Mechanisms of NAFLD development and therapeutic strategies.Nat. Med.201824790892210.1038/s41591‑018‑0104‑929967350
     [Google Scholar]
  5. KleinerD.E. MakhloufH.R. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children.Clin. Liver Dis.201620229331210.1016/j.cld.2015.10.01127063270
     [Google Scholar]
  6. WreeA. BroderickL. CanbayA. HoffmanH.M. FeldsteinA.E. From NAFLD to NASH to cirrhosis — New insights into disease mechanisms.Nat. Rev. Gastroenterol. Hepatol.2013101162763610.1038/nrgastro.2013.14923958599
     [Google Scholar]
  7. AlonsoC. Fernández-RamosD. Varela-ReyM. Martínez-ArranzI. NavasaN. Van LiempdS.M. Lavín TruebaJ.L. MayoR. IlissoC.P. de JuanV.G. Iruarrizaga-LejarretaM. delaCruz-VillarL. MincholéI. RobinsonA. CrespoJ. Martín-DuceA. Romero-GómezM. SannH. PlatonJ. Van EykJ. AspichuetaP. NoureddinM. Falcón-PérezJ.M. AnguitaJ. AransayA.M. Martínez-ChantarM.L. LuS.C. MatoJ.M. Metabolomic identification of subtypes of nonalcoholic steatohepatitis.Gastroenterology2017152614491461.e710.1053/j.gastro.2017.01.01528132890
     [Google Scholar]
  8. LuoW. XuQ. WangQ. WuH. HuaJ. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease.Sci. Rep.2017714461210.1038/srep4461228300213
     [Google Scholar]
  9. TilgH. MoschenA.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis.Hepatology20105251836184610.1002/hep.2400121038418
     [Google Scholar]
  10. TilgH. HotamisligilG.S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance.Gastroenterology2006131393494510.1053/j.gastro.2006.05.05416952562
     [Google Scholar]
  11. RadaP. González-RodríguezÁ. García-MonzónC. ValverdeÁ.M. Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver?Cell Death Dis.202011980210.1038/s41419‑020‑03003‑w32978374
     [Google Scholar]
  12. KoliakiC. SzendroediJ. KaulK. JelenikT. NowotnyP. JankowiakF. HerderC. CarstensenM. KrauschM. KnoefelW.T. SchlensakM. RodenM. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.Cell Metab.201521573974610.1016/j.cmet.2015.04.00425955209
     [Google Scholar]
  13. Neuschwander-TetriB.A. Non-alcoholic fatty liver disease.BMC Med.20171514510.1186/s12916‑017‑0806‑828241825
     [Google Scholar]
  14. MagkosF. FraterrigoG. YoshinoJ. LueckingC. KirbachK. KellyS.C. de las FuentesL. HeS. OkunadeA.L. PattersonB.W. KleinS. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity.Cell Metab.201623459160110.1016/j.cmet.2016.02.00526916363
     [Google Scholar]
  15. NassirF. NAFLD: Mechanisms, treatments, and biomarkers.Biomolecules202212682410.3390/biom1206082435740949
     [Google Scholar]
  16. SanyalA.J. ChalasaniN. KowdleyK.V. McCulloughA. DiehlA.M. BassN.M. Neuschwander-TetriB.A. LavineJ.E. TonasciaJ. UnalpA. Van NattaM. ClarkJ. BruntE.M. KleinerD.E. HoofnagleJ.H. RobuckP.R. NASH CRN Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N. Engl. J. Med.2010362181675168510.1056/NEJMoa090792920427778
     [Google Scholar]
  17. MahadyS.E. WebsterA.C. WalkerS. SanyalA. GeorgeJ. The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis.J. Hepatol.20115561383139010.1016/j.jhep.2011.03.01621703200
     [Google Scholar]
  18. FriedmanS.L. RatziuV. HarrisonS.A. AbdelmalekM.F. AithalG.P. CaballeriaJ. FrancqueS. FarrellG. KowdleyK.V. CraxiA. SimonK. FischerL. Melchor-KhanL. VestJ. WiensB.L. VigP. SeyedkazemiS. GoodmanZ. WongV.W.S. LoombaR. TackeF. SanyalA. LefebvreE. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.Hepatology20186751754176710.1002/hep.2947728833331
     [Google Scholar]
  19. SumidaY. YonedaM. Current and future pharmacological therapies for NAFLD/NASH.J. Gastroenterol.201853336237610.1007/s00535‑017‑1415‑129247356
     [Google Scholar]
  20. NoureddinM. MuthiahM.D. SanyalA.J. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis.Endocrinol. Diabetes Metab.202034e0010510.1002/edm2.10533102791
     [Google Scholar]
  21. MantovaniA. DalbeniA. Treatments for NAFLD: State of art.Int. J. Mol. Sci.2021225235010.3390/ijms2205235033652942
     [Google Scholar]
  22. RongL. ZouJ. RanW. QiX. ChenY. CuiH. GuoJ. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).Front. Endocrinol. (Lausanne)202313108726010.3389/fendo.2022.108726036726464
     [Google Scholar]
  23. TackeF. PuengelT. LoombaR. FriedmanS.L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.J. Hepatol.202379255256610.1016/j.jhep.2023.03.03837061196
     [Google Scholar]
  24. HarrisonS.A. BedossaP. GuyC.D. SchattenbergJ.M. LoombaR. TaubR. LabriolaD. MoussaS.E. NeffG.W. RinellaM.E. AnsteeQ.M. AbdelmalekM.F. YounossiZ. BaumS.J. FrancqueS. CharltonM.R. NewsomeP.N. LanthierN. SchiefkeI. MangiaA. PericàsJ.M. PatilR. SanyalA.J. NoureddinM. BansalM.B. AlkhouriN. CasteraL. RudrarajuM. RatziuV. MAESTRO-NASH Investigators A phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis.N. Engl. J. Med.2024390649750910.1056/NEJMoa230900038324483
     [Google Scholar]
  25. RayK. Resmetirom proves positive for NASH with liver fibrosis.Nat. Rev. Gastroenterol. Hepatol.202421421810.1038/s41575‑024‑00909‑038360990
     [Google Scholar]
  26. ZhouZ. ZhangJ. YouL. WangT. WangK. WangL. KongX. GaoY. SunX. Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.Front. Endocrinol. (Lausanne)202213100072710.3389/fendo.2022.100072736204095
     [Google Scholar]
  27. ZhaoC. DingH. HuZ. DuY. ZhouL. ZhouP. WangL. Pharmacodynamic study and mechanism of action of Lingguizhugan decoction in the intervention of non-alcoholic fatty liver disease.J. Hainan Med. Univ.20241293810.13210/j.cnki.jhmu.20230927.002
     [Google Scholar]
  28. National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association & Fatty Liver Expert Committee, Chinese Medical Doctor Association. (2018). Guidelines for the prevention and treatment of nonalcoholic fatty liver disease(2018 updated version).J. Pract. Liver Dis.2018212177186
     [Google Scholar]
  29. LiuN. YangJ. MaW. LiC. AnL. ZhangX. ZouQ. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.J. Ethnopharmacol.202228811499910.1016/j.jep.2022.11499935051605
     [Google Scholar]
  30. WenH. LiangY. DengX. Clinical study of Ling Gui Zhu Gan Decoction combined with polyene phosphatidylcholine in the treatment of nonalcoholic fatty liver disease.Henan Traditional Chinese Medicine202242111639164310.16367/j.issn.1003‑5028.2022.11.0347
     [Google Scholar]
  31. LuoH. HeW. LiD. LiW. ZhaoQ. Effects of Ling Gui Zhu Gan Decoction on oxidative stress level and lipid metabolism in patients with non-alcoholic fatty liver disease with spleen deficiency and phlegm stasis.World J. Integr. Med202217479279510.13935/j.cnki.sjzx.220429
     [Google Scholar]
  32. DongL. CaoX. ChengL. XueH. GuoX. YangY. Observation on the efficacy of Ling Gui Zhu Gan Decoction combined with polyene phosphatidylcholine in the treatment of nonalcoholic fatty liver disease.Hainan Med20223313638
     [Google Scholar]
  33. ChenX-H. A randomized controlled study on the improvement of non-alcoholic fatty liver disease by adding Ling Gui Zhu Gan Decoction combined with calorie restriction.Thesis Guangzhou University of Traditional Chinese Medicine2021
     [Google Scholar]
  34. ShenJ. LiangM. HuZ. JiangS. Observation on the efficacy of Ling Gui Zhu Gan Decoction combined with Silymarin Capsules in the treatment of nonalcoholic fatty liver disease.Inner Mongol. Tradit. Chin. Med.2020399585910.16040/j.cnki.cn15‑1101.2020.09.036
     [Google Scholar]
  35. XueX. XieC. Clinical effect and mechanism of action of Yin Chen Ling Gui Zhu Gan Decoction in the treatment of nonalcoholic steatohepatitis.Chin. Med.2020156907911
     [Google Scholar]
  36. JingX. Study on the effect of Ling Gui Zhu Gan Decoction in intervening non-alcoholic fatty liver disease with spleen yang deficiency formula.Thesis, Shanghai University of Traditional Chinese Medicine2020
     [Google Scholar]
  37. YuX. WangW. JinJ. PanJ. ZhangH. XingL. Ling Gui Zhu Gan Decoction combined with probiotics for the treatment of nonalcoholic fatty liver disease.J. Changchun Univ. Tradit. Chin. Med.201935589189410.13463/j.cnki.cczyy.2019.05.022
     [Google Scholar]
  38. SunS. WangY. Clinical efficacy of self-prepared Ling Gui Zhu Gan Decoction plus reduction combined with western medicine drugs in the treatment of non-alcoholic fatty liver disease.PharmacoEconomics Chin. Med.20191496568
     [Google Scholar]
  39. SongQ. LiH. Intervention study on serum NO level in patients with nonalcoholic fatty liver disease by adding Ling Gui Zhu Gan Decoction.Inner Mongol. Tradit. Chin. Med.201433103410.16040/j.cnki.cn15‑1101.2014.10.019
     [Google Scholar]
  40. SongQ. LiH. Clinical study on the treatment of nonalcoholic fatty liver disease by adding Ling Gui Zhu Gan Decoction.Sichuan Tradit. Chin. Med.201331086062
     [Google Scholar]
  41. LiJ. Clinical study on the treatment of non-alcoholic fatty liver disease (phlegm and stasis mutual conjugation syndrome) by adding flavor Ling Gui Zhu Gan granules.Thesis, Guangxi University of Chinese Medicine2011
     [Google Scholar]
  42. ZhangY. Effects of poria cocos complex extract on blood glucose and lipid levels in type 2 diabetic rats.Jilin Daxue Xuebao. Yixue Ban20204605937941
     [Google Scholar]
  43. CaoL. XuE. ZhengR. ZhangchenZ. ZhongR. HuangF. YeJ. SunH. FanY. XieS. ChenY. XuY. CaoJ. CaoW. LiuC. Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages.Chin. Med.2022171710.1186/s13020‑021‑00559‑334983596
     [Google Scholar]
  44. DangY. HaoS. ZhouW. ZhangL. JiG. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules.BMC Complement. Altern. Med.2019191810.1186/s12906‑018‑2424‑130616587
     [Google Scholar]
  45. HuangJ. DuY. YanJ. HuY. LiX. Effects of adding Ling Gui Zhu Gan Decoction on serum resistin, lipocalin, insulin, and insulin resistance in rats with metabolic syndrome.Chin. J. Exp. Formulas2013190622723010.13422/j.cnki.syfjx.2013.06.079
     [Google Scholar]
  46. CaoL. Molecular mechanism study of Ling Gui Zhu Gan decoction in treating non-alcoholic fatty liver disease by inhibiting STING-mediated signaling pathway.Thesis, Nanjing University of Traditional Chinese Medicine2022
     [Google Scholar]
  47. BuL. Experimental study on the effect of TNF-α and Leptin on cytokines in NAFLD rats by adding flavor Ling Gui Zhu Gan Decoction based on turbid and stasis treatment.Thesis, Shanxi University of Traditional Chinese Medicine2018
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303323071241022053842
Loading
Lingguizhugan Decoction in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Endocr Metab Immune Disord Drug Targets 25, 1060 (2025); https://doi.org/10.2174/0118715303323071241022053842
/content/journals/emiddt/10.2174/0118715303323071241022053842
/content/journals/emiddt/10.2174/0118715303323071241022053842
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): controlled trials; Ling Gui Zhu Gan Decoction; meta-analysis; non-alcoholic fatty liver disease; systematic review; traditional Chinese medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test